Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

High frequency of mutations of the PIK3CA gene in human cancers.

Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE.

Science. 2004 Apr 23;304(5670):554. Epub 2004 Mar 11. No abstract available.

2.

Multiplexed assays for detection of mutations in PIK3CA.

Board RE, Thelwell NJ, Ravetto PF, Little S, Ranson M, Dive C, Hughes A, Whitcombe D.

Clin Chem. 2008 Apr;54(4):757-60. doi: 10.1373/clinchem.2007.098376.

3.

Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas.

Lee JW, Soung YH, Seo SH, Kim SY, Park CH, Wang YP, Park K, Nam SW, Park WS, Kim SH, Lee JY, Yoo NJ, Lee SH.

Clin Cancer Res. 2006 Jan 1;12(1):57-61.

4.

High-throughput mutational analysis of the human cancer genome.

Ma PC, Zhang X, Wang ZJ.

Pharmacogenomics. 2006 Jun;7(4):597-612. Review.

PMID:
16753007
5.

Somatic mutation of pro-cell death Bif-1 gene is rare in common human cancers.

Kim MS, Yoo NJ, Lee SH.

APMIS. 2008 Oct;116(10):939-40. doi: 10.1111/j.1600-0463.2008.01091.x. No abstract available.

PMID:
19132989
6.

Somatic mutation of PINX1 gene is rare in common solid cancers.

Kim MS, Kim SS, Yoo NJ, Lee SH.

APMIS. 2012 Sep;120(9):770-1. doi: 10.1111/j.1600-0463.2012.02901.x. Epub 2012 Mar 30. No abstract available.

PMID:
22882268
7.

Oncogenic mutations of PIK3CA in human cancers.

Samuels Y, Velculescu VE.

Cell Cycle. 2004 Oct;3(10):1221-4. Epub 2004 Oct 12.

PMID:
15467468
8.

Absence of GNAS and EGFL6 mutations in common human cancers.

Lee SH, Jeong EG, Soung YH, Lee JW, Yoo NJ, Lee SH.

Pathology. 2008 Jan;40(1):95-7. No abstract available.

PMID:
18038328
9.

Rare somatic mutation of pro-apoptotic BAX and BAK genes in common human cancers.

Kim MS, Kim SS, Yoo NJ, Lee SH.

Tumori. 2012 Nov;98(6):149e-51e. doi: 10.1700/1217.13509.

PMID:
23389372
10.

Molecular alterations of Ras-Raf-mitogen-activated protein kinase and phosphatidylinositol 3-kinase-Akt signaling pathways in colorectal cancers from a tertiary hospital at Kuala Lumpur, Malaysia.

Yip WK, Choo CW, Leong VC, Leong PP, Jabar MF, Seow HF.

APMIS. 2013 Oct;121(10):954-66. doi: 10.1111/apm.12152. Epub 2013 Aug 29.

PMID:
23992303
11.

A PIK3CA mutation detected in plasma from a patient with synchronous primary breast and lung cancers.

Jelovac D, Beaver JA, Balukrishna S, Wong HY, Toro PV, Cimino-Mathews A, Argani P, Stearns V, Jacobs L, VanDenBerg D, Kessler J, Jeter S, Park BH, Wolff AC.

Hum Pathol. 2014 Apr;45(4):880-3. doi: 10.1016/j.humpath.2013.10.016. Epub 2013 Oct 31.

12.

Characteristics and prevalence of KRAS, BRAF, and PIK3CA mutations in colorectal cancer by high-resolution melting analysis in Taiwanese population.

Hsieh LL, Er TK, Chen CC, Hsieh JS, Chang JG, Liu TC.

Clin Chim Acta. 2012 Oct 9;413(19-20):1605-11. doi: 10.1016/j.cca.2012.04.029. Epub 2012 May 8.

PMID:
22579930
13.

Phosphatidylinositol-3-kinase α catalytic subunit gene somatic mutations in bronchopulmonary neuroendocrine tumours.

Capodanno A, Boldrini L, Alì G, Pelliccioni S, Mussi A, Fontanini G.

Oncol Rep. 2012 Nov;28(5):1559-66. doi: 10.3892/or.2012.2017. Epub 2012 Sep 4.

14.

Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias.

Kim MS, Jeong EG, Yoo NJ, Lee SH.

Br J Cancer. 2008 May 6;98(9):1533-5. doi: 10.1038/sj.bjc.6604212. Epub 2008 Apr 8.

15.

Kinase domain mutation of MAP2K4 is rare in gastric, colorectal and lung carcinomas.

Lee JW, Soung YH, Kim SY, Nam SW, Park WS, Lee JY, Yoo NJ, Lee SH.

Pathology. 2006 Jun;38(3):263-4. No abstract available.

PMID:
16753753
16.

Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review.

Liao X, Morikawa T, Lochhead P, Imamura Y, Kuchiba A, Yamauchi M, Nosho K, Qian ZR, Nishihara R, Meyerhardt JA, Fuchs CS, Ogino S.

Clin Cancer Res. 2012 Apr 15;18(8):2257-68. doi: 10.1158/1078-0432.CCR-11-2410. Epub 2012 Feb 22.

17.

Mutation of the PIK3CA oncogene in human cancers.

Karakas B, Bachman KE, Park BH.

Br J Cancer. 2006 Feb 27;94(4):455-9. Review.

18.

PIK3CA mutations and copy number gains in human lung cancers.

Yamamoto H, Shigematsu H, Nomura M, Lockwood WW, Sato M, Okumura N, Soh J, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Date H, Lam WL, Minna JD, Gazdar AF.

Cancer Res. 2008 Sep 1;68(17):6913-21. doi: 10.1158/0008-5472.CAN-07-5084.

19.

High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer.

Simi L, Pratesi N, Vignoli M, Sestini R, Cianchi F, Valanzano R, Nobili S, Mini E, Pazzagli M, Orlando C.

Am J Clin Pathol. 2008 Aug;130(2):247-53. doi: 10.1309/LWDY1AXHXUULNVHQ.

20.

Differential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class IA phosphoinositide 3-kinase.

Pang H, Flinn R, Patsialou A, Wyckoff J, Roussos ET, Wu H, Pozzuto M, Goswami S, Condeelis JS, Bresnick AR, Segall JE, Backer JM.

Cancer Res. 2009 Dec 1;69(23):8868-76. doi: 10.1158/0008-5472.CAN-09-1968. Epub 2009 Nov 10.

Items per page

Supplemental Content

Write to the Help Desk